echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Better enters the contrast agent market!

    Better enters the contrast agent market!

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, February 23.
    On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
    The original research company of this product is Bayer.
    In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
    3 billion yuan.
    Currently, only original research is imported in China.
     
    Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
    Source: CDE official website
     
    Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
    Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
    According to data from Menet.
    com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
    In the first half of 2020, affected by the epidemic, the sales scale declined.
    The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
    There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
     
      Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
    In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
    The injection is expected to hit the first reviewer.
     
      Source: Minet database, CDE official website
     
      The review data statistics are as of February 22, 2021.
    If there are any errors or omissions, please correct me.
      Medical Network, February 23.
    On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
    The original research company of this product is Bayer.
    In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
    3 billion yuan.
    Currently, only original research is imported in China.
     
      Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
      Source: CDE official website
     
      Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      According to data from Menet.
    com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
    In the first half of 2020, affected by the epidemic, the sales scale declined.
    The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
    There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
     
      Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
    In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
    The injection is expected to hit the first reviewer.
     
      Source: Minet database, CDE official website
     
      The review data statistics are as of February 22, 2021.
    If there are any errors or omissions, please correct me.
      Medical Network, February 23.
    On February 20, Chengdu Better Pharmaceutical's application for the imitation of iopromide injections for Category 4 listing was accepted, and it was the company's first contrast agent to be listed on the market.
    The original research company of this product is Bayer.
    In 2019, its global sales exceeded 300 million euros, and its terminal sales in public medical institutions in China also exceeded 1.
    3 billion yuan.
    Currently, only original research is imported in China.
     
      Figure 1: Registration status of iopromide injection declared by Chengdu Better Pharmaceutical
      Source: CDE official website
     
      Figure 2: 2020H1 China's public medical institutions TOP20 brands of terminal contrast agents
      Source: Mi Nei.
    com, China's public medical institutions terminal competition pattern
     
      According to data from Menet.
    com, in 2019, the market size of terminal contrast media for urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) has risen to 15 billion yuan.
    In the first half of 2020, affected by the epidemic, the sales scale declined.
    The top three brands in the TOP20 have been taken by domestic pharmaceutical companies, and Bayer's iopromide injection ranked fourth.
    There is currently no domestic imitation approval for this product, only Chengdu Better declared for listing.
    Hospital hospital hospital
     
      Table 1: The status of products declared and marketed by Better Pharmaceuticals since 2021
      Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database
     
      Iopromide injection is the first contrast agent declared for marketing by Better Pharmaceuticals.
    In addition, since 2021, the company has also applied for the listing of a number of high-end generic drugs, including tranexamic acid injection, phloroglucinol injection, and salbutamol sulfate.
    The injection is expected to hit the first reviewer.
     
      Source: Minet database, CDE official website
     
      The review data statistics are as of February 22, 2021.
    If there are any errors or omissions, please correct me.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.